A charger for an electronic nicotine delivery systems (“ENDS”) device, which may include aerosol delivery devices provides functionality for authentication, including age verification. Such devices may be restricted based on age or other factors that require some form of authentication, verification, and/or identification to satisfy the restriction. The accessory or charger may provide or connect with a verification system for confirming an age of a user. If the authentication or verification is not satisfied, the charger or accessory will not charge the device, rendering it unusable.

A mist inhaler device (200) for generating a mist for inhalation by a user. The device includes a mist generator device (201) and a driver device (202). The driver device (202) is configured to drive the mist generator device (201) at an optimum frequency to maximise the efficiency of mist generation by the mist generator device (201).

A dispersion device includes a first dispersion generating system, a second dispersion generating system and an outlet end element including a first outlet corresponding to the first dispersion generating system and a second outlet corresponding to the second dispersion generating system.

A device is disclosed for the preparation of nebulised droplets, for inhalation. The device has: a surface acoustic wave (SAW) transmission surface; a SAW transducer adapted to generate and propagate SAWs along the SAW transmission surface; and an array of cavities opening at the SAW transmission surface for containing a liquid. In operation, SAWs propagating along the SAW transmission surface interact with the liquid in the cavities to produce nebulised droplets of the liquid. Operation of the device results in a nebulised plume of droplets of average diameter in the range 1-5 μm.

A portable device for treatment of migraine having a desktop unit defining an airpath through a desiccant, a heat sink, an air mover and an air outlet, and a tubeset including a tube having one end for connecting to the desktop air outlet and a second end connected to a handheld unit, the handheld unit including a water compartment, and a nebulizer/transducer for introducing water droplets into the air stream. A nasal pillow is provided at the end of the handheld unit for placing against a user's nose.

A mist inhaler device (200) for generating a mist comprising a therapeutic for inhalation by a user. The device comprises a mist generator device (201) and a driver device (202). The driver device (202) is configured to drive the mist generator device (201) at an optimum frequency to maximise the efficiency of mist generation by the mist generator device (201).

A hookah device (202) which attaches to a hookah (246). The hookah device (202) comprises a plurality of ultrasonic mist generator devices (201) for generating a mist for inhalation by a user. The hookah device (202) comprises a driver device (202) which controls the mist generator devices (201) to maximize the efficiency of mist generation by the mist generator devices (201) and optimize mist output from the hookah device (202).

Nebulization of a medicament for delivery to a subject is monitored. In one embodiment, whether there is any medicament to be nebulized, a rate of nebulization, and/or other aspects of the nebulization of the medicament are monitored. Information related to the one or more monitored aspects of the nebulization may be provided to a subject. For example, by monitoring whether there is any medicament to be nebulized, whether the nebulization of the medicament is complete may be determined.

A method for estimating an inhale dose when a drug is delivered to a person using an inhaler is disclosed. A predicted inhale dose (PID) of the drug is estimated based on at least one first-type parameter and at least one second-type parameter. The first-type parameter is related to a breath pattern of the person, and the second-type parameter is related to the inhaler.

The present disclosure relates to a pharmaceutical composition comprising an inhalable immunosuppressive macrocyclic active ingredient for use in the prevention or treatment of a pulmonary disease or condition in a subject, wherein the pharmaceutical composition is administered to the subject by inhalation in form of an aerosol, and wherein the aerosol is generated by nebulization of the pharmaceutical composition using a nebulizer (100), the nebulizer comprising: a) an aerosol generator (101) comprising: —a fluid reservoir (103) for holding the pharmaceutical composition or an interface configured to connect a fluid reservoir, and a vibratable membrane (110) having a plurality of apertures, the apertures being adapted to produce an aerosol comprising droplets having a mass median aerodynamic diameter (MMAD) of up to about 4.0 gm as measured with a 0.9% (w/v) aqueous solution of sodium chloride; b) a chamber (105) for temporarily accommodating the aerosol generated by the aerosol generator (101), the chamber having an inner lumen with a volume in the range of from about 50 to about 150 ml; and c) a mouthpiece (40) for delivering the aerosol supplied by the nebulizer (100) to the subject, the mouthpiece having an exhalation filter (30).